Result of AGM
Updated : 18:12
BIOPHARMA CREDIT PLC
(THE "COMPANY")
RESULT OF ANNUAL GENERAL MEETING
The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions were passed on a show of hands.
The proxy votes received in relation to these resolutions were as follows:
Resolutions
| Votes For
| % | Votes Against
| % | Votes at Chairman's Discretion | Votes Withheld |
1: To receive and accept the annual report and financial statements
| 895,570,264 | 100 | 0 | 0 | 0 | 0 |
2: To approve the Directors' Remuneration Report
| 895,570,264 | 100 | 0 | 0 | 0 | 0 |
3: To re-elect Jeremy Sillem as a Director
| 895,570,264 | 100 | 0 | 0 | 0 | 0 |
4: To re-elect Colin Bond as a Director
| 895,570,264 | 100 | 0 | 0 | 0 | 0 |
5: To re-elect Duncan Budge as a Director
| 895,570,264 | 100 | 0 | 0 | 0 | 0 |
6: To re-elect Harry Hyman as a Director
| 866,249,863 | 96.73 | 29,320,401 | 3.27 | 0 | 0 |
7: To elect Stephanie Léouzon as a Director
| 895,570,264 | 100 | 0 | 0 | 0 | 0 |
8: To re-appoint Pricewaterhouse Coopers LLP as Auditor to the Company
| 895,570,264 | 100 | 0 | 0 | 0 | 0 |
9: To authorise the Directors to determine the remuneration of the Auditor
| 895,570,264 | 100 | 0 | 0 | 0 | 0 |
10: To approve the Company's dividend payment policy
| 895,570,264 | 100 | 0 | 0 | 0 | 0 |
11: To authorise the Company to make market purchases of ordinary shares
| 790,025,298 | 89.98 | 88,000,000 | 10.02 | 0 | 17,544,966 |
12: To authorise the Company to hold general meetings on 14 clear days' notice
| 895,570,264 | 100 | 0 | 0 | 0 | 0 |
A copy of resolutions 11 and 12 has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM
19 June 2019
Enquiries:
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0) 20 7466 5000
Biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist debt investor to the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.